Home » Stocks » VNDA

Vanda Pharmaceuticals Inc. (VNDA)

Stock Price: $16.31 USD -1.56 (-8.73%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $16.71 +0.40 (2.45%) Jul 30, 7:18 PM
Market Cap 906.25M
Revenue (ttm) 258.53M
Net Income (ttm) 32.44M
Shares Out 55.58M
EPS (ttm) 0.57
PE Ratio 28.56
Forward PE 30.30
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $16.31
Previous Close $17.87
Change ($) -1.56
Change (%) -8.73%
Day's Open 17.73
Day's Range 15.85 - 18.18
Day's Volume 2,495,219
52-Week Range 9.00 - 21.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 days ago - Zacks Investment Research

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and -4.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 6.25% year over year to $0.17, which beat...

4 days ago - Benzinga

WASHINGTON, July 28, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021. "Vanda had anoth...

4 days ago - PRNewsWire

WASHINGTON, July 21, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the mar...

1 week ago - PRNewsWire

Vanda (VNDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the ...

1 month ago - Zacks Investment Research

WASHINGTON, May 12, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the following investor conferences: Bank of America...

2 months ago - PRNewsWire

With the trading day about halfway over, the markets were getting crushed. The Nasdaq was again facing the worst of this, with the index down about 2%.

Other stocks mentioned: AMZN, CAT, DIS, EA, AWK, MIME
2 months ago - 24/7 Wall Street

Vanda (VNDA) delivered earnings and revenue surprises of 7.14% and 166.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

WASHINGTON, May 5, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2021. "Despite seasonal ...

2 months ago - PRNewsWire

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

WASHINGTON, April 20, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2021 on Wednesday, May 5, 2021, after the marke...

3 months ago - PRNewsWire

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals, Inc. (Nasdaq: VNDA)

4 months ago - Business Wire

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending secu...

4 months ago - Business Wire

The IBD SmartSelect Composite Rating for Vanda Pharmaceuticals increased from 78 to 97 Friday. The post Vanda Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating appeared first on I...

5 months ago - Investors Business Daily

WASHINGTON, Feb. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2020...

5 months ago - PRNewsWire

WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, February 10, 20...

5 months ago - PRNewsWire

The biotech's sleep drug Hetlioz gained an expanded approval.

7 months ago - The Motley Fool

News of an update from the U.S. Food and Drug Administration (FDA) pushed Vanda Pharmaceuticals Inc.

7 months ago - 24/7 Wall Street

WASHINGTON, Dec. 1, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ® (tasimelteon) capsule an...

8 months ago - PRNewsWire

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: ANIP, SRGA, PETS, SRDX
8 months ago - GuruFocus

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Vanda (VNDA) delivered earnings and revenue surprises of 37.50% and -5.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cataly...

Other stocks mentioned: CPRX, PRDO, SBR, XBIT
9 months ago - GuruFocus

WASHINGTON, Oct. 28, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2020. "Vanda conti...

9 months ago - PRNewsWire

WASHINGTON, Oct. 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IN...

9 months ago - PRNewsWire

WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020, after the m...

9 months ago - PRNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, MRSN, NVAX, REGN, TECH, XBIT
10 months ago - Investopedia

WASHINGTON, Aug. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

11 months ago - PRNewsWire

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) took another big step forward in the fight against COVID-19 on Tuesday morning.

11 months ago - 24/7 Wall Street

WASHINGTON, Aug. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

11 months ago - PRNewsWire

Vanda Pharmaceuticals Is Still Undervalued Despite Strong Performance During The Pandemic

11 months ago - Seeking Alpha

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

11 months ago - PRNewsWire

WASHINGTON, July 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the ma...

1 year ago - PRNewsWire

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDA...

1 year ago - Business Wire

Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.

1 year ago - Zacks Investment Research

WASHINGTON, July 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individ...

1 year ago - PRNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, INVA, NVAX, TRIL, VRTX, XBIT
1 year ago - Investopedia

Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

1 year ago - Benzinga

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Cl...

1 year ago - PRNewsWire

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals...

1 year ago - PRNewsWire

No matter how much courage an investor has, investing in cheap stocks that have pending whistleblower lawsuits against them just isn't a good idea.

1 year ago - The Motley Fool

Third-quarter results from a COVID-19 trial could send this stock soaring.

1 year ago - The Motley Fool

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Vanda Pharmaceuticals: Undervalued Despite Its COVID-19 Treatment Potential

1 year ago - Seeking Alpha

Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.

1 year ago - Zacks Investment Research

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment... [Read more...]

Industry
Biotechnology
IPO Date
Apr 12, 2006
CEO
Mihael Polymeropoulos
Employees
292
Stock Exchange
NASDAQ
Ticker Symbol
VNDA
Full Company Profile

Financial Performance

In 2020, VNDA's revenue was $248.17 million, an increase of 9.23% compared to the previous year's $227.19 million. Earnings were $23.34 million, a decrease of -79.80%.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is an increase of 41.02% from the latest price.

Price Target
$23.00
(41.02% upside)
Analyst Consensus: Strong Buy